Literature DB >> 16025547

Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production.

R Koldej1, P Cmielewski, A Stocker, D W Parsons, D S Anson.   

Abstract

BACKGROUND: We have previously described a five-plasmid HIV-1 vector system that utilises a codon-optimised gagpol gene. While this system was shown to be safer than systems using proviral type helpers, the titre of virus produced was relatively low. Therefore, a process of optimising all aspects of virus production was initiated.
METHODS: A systematic approach was taken to the optimisation of virus production by transient expression using a five-plasmid packaging system. Codon-manipulation was used to reduce homology between helper and vector constructs. Ultrafiltration and ultracentrifugation were used for large-scale virus production.
RESULTS: We describe codon-optimised reading frames for Tat and Rev and the optimisation of virus production. The optimisation process resulted in an increase in virus titre of 7- to 8-fold. Several other approaches to increasing viral titre described by others proved ineffective in our system after it had been optimised. In addition, we show that by varying the ratio of the GagPol helper construct to vector, the infectivity of the virus could be controlled. The use of a novel codon-optimised HIV-1 GagPol expression construct with reduced homology to vector sequences significantly reduced transfer of gagpol sequences to transduced cells. Virus could be collected in serum-free medium without a significant loss of titre, which facilitated subsequent processing. Processing using a combination of ultrafiltration and ultracentrifugation allowed efficient and rapid processing of litre volumes of virus supernatant.
CONCLUSIONS: By taking a systematic approach to optimising all aspects of our five-plasmid lentiviral vector system we improved titre, safety, large-scale production, and demonstrated that infectivity could be specifically controlled. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025547     DOI: 10.1002/jgm.803

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  14 in total

1.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Analysis of partial recombinants in lentiviral vector preparations.

Authors:  Seraphin Kuate; Michael P Marino; Jakob Reiser
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

3.  Correction of methylmalonic aciduria in vivo using a codon-optimized lentiviral vector.

Authors:  Edward S Y Wong; Chantelle McIntyre; Heidi L Peters; Enzo Ranieri; Donald S Anson; Janice M Fletcher
Journal:  Hum Gene Ther       Date:  2014-04-02       Impact factor: 5.695

4.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

5.  Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses.

Authors:  Xenia Kaidonis; Wan Chin Liaw; Ainslie Derrick Roberts; Marleesa Ly; Donald Anson; Sharon Byers
Journal:  Eur J Hum Genet       Date:  2009-08-19       Impact factor: 4.246

6.  Airway gene transfer in a non-human primate: lentiviral gene expression in marmoset lungs.

Authors:  N Farrow; D Miller; P Cmielewski; M Donnelley; R Bright; D W Parsons
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo.

Authors:  Jessamy C Tiffen; Charles G Bailey; Cynthia Ng; John E J Rasko; Jeff Holst
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

8.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

9.  Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repair.

Authors:  Rachel M Koldej; Donald S Anson
Journal:  BMC Biotechnol       Date:  2009-10-07       Impact factor: 2.563

10.  Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography.

Authors:  Robert H Kutner; Sharon Puthli; Michael P Marino; Jakob Reiser
Journal:  BMC Biotechnol       Date:  2009-02-16       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.